Egi Moritoki
Department of Anesthesiology and Resuscitology, Okayama University Medical School, Okayama 700-8558.
Masui. 2011 Mar;60(3):285-92.
Hyperglycemia is common in critically ill patients with approximately 90% of patients treated in an intensive care unit (ICU) developing blood glucose concentrations greater than 110 mg x dl(-1). Recently the international multicentre NICE-SUGAR study reported increased mortality with adopting intensive glucose control for critically ill patients and recent meta-analyses do not support this approach. Whilst the initial trials in Leuven produced enthusiasm and recommendations for intensive blood glucose control, the results of the NICE-SUGAR study have resulted in the more moderate recommendation to target a blood glucose concentration between 144 and 180 mg x dl(-1). As critical care practitioners paid greater attention to glycemic control it became clear that currently used point-of-care measuring systems are not accurate enough to target tight glucose control. Unresolved issues include whether increased blood glucose variability is inherently harmful and whether even moderate hypoglycemia can be tolerated in the quest for tighter blood glucose control. Until another level I evidence will be available, clinicians would be well advised to hasten slowly and abide by the age-old adage to "first, do no harm".
高血糖在危重症患者中很常见,在重症监护病房(ICU)接受治疗的患者中,约90%的患者血糖浓度超过110mg/dl(-1)。最近,国际多中心NICE-SUGAR研究报告称,对危重症患者采用强化血糖控制会增加死亡率,近期的荟萃分析也不支持这种方法。虽然鲁汶的初步试验激发了人们对强化血糖控制的热情并提出了相关建议,但NICE-SUGAR研究的结果导致了更为适度的建议,即把血糖浓度目标设定在144至180mg/dl(-1)之间。随着重症监护从业者对血糖控制的关注度提高,很明显目前使用的即时检测系统不够精确,无法实现严格的血糖控制目标。尚未解决的问题包括血糖变异性增加是否本质上有害,以及在追求更严格的血糖控制时,即使是中度低血糖是否可以耐受。在获得另一项一级证据之前,建议临床医生谨慎行事,遵循“首先,不造成伤害”这句古老格言。